Silexion Therapeutics Corp (SLXN) - News Archive

In a significant advancement for cancer treatment, Silexion Therapeutics announced promising preclinical results regarding its novel therapeutic candidate, SIL204. The company has demonstrated that SIL204 effectively re...

: Silexion Therapeutics has announced the completion of an innovative expanded development plan for its promising therapeutic candidate, SIL204. This plan will be detailed during a presentation at the 2025 NeauxCancer C...

In the ever-evolving landscape of oncology, Silexion Therapeutics has emerged as a notable contender with significant strides in its preclinical pipeline, primarily focusing on KRAS-driven solid tumors. The latest finan...

In recent developments that could potentially transform the landscape of pancreatic cancer therapy, Silexion Therapeutics has reported groundbreaking initial data regarding its novel therapeutic agent, SIL204. This arti...

In the ever-evolving landscape of biomedical innovation, Silexion Therapeutics (NASDAQ: SLXN) is on the verge of potentially groundbreaking advancements in the treatment of KRAS-driven cancers. Recently, PESG Research r...

In a significant advancement in cancer therapeutics, Silexion Therapeutics has recently released encouraging preclinical data regarding its investigational drug, SIL-204. This novel agent has exhibited impressive synerg...

Silexion Therapeutics Bolsters Financial Position with $5 Million Public Offering in Pursuit of Novel RNAi Cancer Therapies Silexion Therapeutics Corp: Strategic Funding for Future Innovation In a significant move to ad...

Silexion Therapeutics and Evonik Collaborate on Breakthrough siRNA Formulation for KRAS-Mutated Cancers In a significant advancement for the field of cancer therapeutics, Silexion Therapeutics has announced a strategic...

In the fast-paced world of biotechnology, Silexion Therapeutics has recently made significant strides that could redefine its trajectory in cancer treatment. The dual announcement of a new board member and a strategic s...

Silexion s Strategic Stock Split: A Step Toward Growth and ComplianceIn a move that combines strategic foresight with regulatory necessity, Silexion Therapeutics has announced that trading on a split-adjusted basis will...

Silexion Therapeutics to Showcase Innovative RNAi Therapies at Noble Capital Markets Conference GRAND CAYMAN, CAYMAN ISLANDS Silexion Therapeutics Corp. (NASDAQ: SLXN), a forward-thinking, clinical-stage biotech company...

GRAND CAYMAN, Cayman Islands Silexion Therapeutics Corp. (NASDAQ: SLXN) has announced a significant breakthrough in its ongoing efforts to develop treatments for KRAS-driven cancers. As a clinical-stage biotechnology fi...

In the competitive landscape of precision oncology, Silexion Therapeutics (NASDAQ: SLXN) has begun to carve out a niche as a pioneering force in RNA interference (RNAi) therapy, particularly focusing on tackling the for...

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination: An Overview of Future Potential MarketsIn a significant development for the biotechnology and pharmaceutical indust...